Two targeted therapies in development have demonstrated encouraging activity as potential treatments targeting hard-to-target driver alterations in lung cancer. During the 2019 ASCO Annual Meeting, Christine M. Lovly, MD, PhD, reviewed the early promising findings for TAK-788 for patients with non–small cell lung cancer harboring <em>EGFR</em> exon 20 insertions and for BLU-667 for patients with <em>RET </em>rearrangements.
Christine M. Lovly, MD, PhD
Two targeted therapies in development have demonstrated encouraging activity as potential treatments targeting hard-to-target driver alterations in lung cancer. During the 2019 ASCO Annual Meeting, Christine M. Lovly, MD, PhD, reviewed the early promising findings for TAK-788 for patients with nonsmall cell lung cancer (NSCLC) harboring EGFRexon 20 insertions and for BLU-667 for patients withRETrearrangements.
In the first study,1TAK-788 demonstrated a confirmed objective response rate (ORR) of 43% (95% CI, 24%-63%) and a disease control rate (DCR) of 86% (95% CI, 67%-96%) for patients withEGFRexon 20 insertions. The confirmed ORR consisted of 12 partial responses (PRs), with an additional 3 PRs that were not yet confirmed by a second scan.
In the second early stage study,2BLU-667 showed an ORR of 58% (95% CI, 43%-72%) for patients withRETfusion-positive advanced NSCLC, with a DCR of 96% (95% CI, 86%-99%). In those treated with prior platinum-based chemotherapy, the ORR was 60% (95% CI, 42%-76%) with a DCR of 100% (95% CI, 90%-100%).
“These are not new targets...but they are complex targets. These are not targets that are necessarily easy to build drugs against,” said Lovly, from Vanderbilt-Ingram Cancer Center. “EGFRexon 20 insertions are quite heterogenous at the molecule level. Likewise, RET alterations are another complex target that are very heterogenous at the molecular level."
Exon 20 is the third most common alteration inEGFR, following exon 19 and exon 21, which are successfully targeted by other TKIs. Despite efficacy in other types of activating mutations, TKIs are largely ineffective for those with insertions in exon 20.
TAK-788 was examined in a multi-cohort phase I/II trial for patients with advanced NSCLC with different disease characteristics. In a dose escalation phase of the study, the maximum tolerated dose was determined to be 160 mg daily. Twenty-eight patients from the trial who were treated with 160 mg were analyzed for the presentation at the ASCO meeting (22 from cohort 1 and 6 from the dose escalation). Safety data were available for 137 patients across all cohorts treated at various doses, and specifically for 72 patients who received the 160 mg dose across all cohorts.
Forty-three percent of patients in this analysis had brain metastases at baseline. The median age of patients was 62 years, and the most common ECOG status was 1 (79%). The median number of prior systemic cancer regimens was 3, including prior checkpoint inhibitors (61%) and EGFR- or HER2-directed TKIs (18%).
The confirmed ORR was 25% in patients with baseline brain metastases, with a DCR of 67%. In those without brain metastases, the confirmed ORR was 56% and the DCR was 100%. The median progression-free survival (PFS) was 7.3 months across all patients in the analysis and was 3.7 months and 8.1 months for those with and without brain metastases, respectively.
“The numbers are small here, so it is difficult to divide out too many subsets,” cautioned senior study author Gregory J. Riely, MD, from the Memorial Sloan Kettering Cancer Center. “But if you compare patients with baseline brain metastases to those without baseline brain metastases there is a numerically lower response rate in those with baseline brain metastases as well as a shorter progression-free survival.”
Grade ≥3 treatment-emergent adverse events (AEs) occurred in 63% of patients treated at the 160 mg dose across cohorts and in 61% of those treated with TAK-788 at any dose. Grade ≥3 treatment-related AEs occurred in 40% and 32% of patients in the 160 mg and any dose arms, respectively. The most common treatment-related grade ≥3 AEs in at the 160 mg dose were diarrhea (18%), nausea (6%), increase lipase (6%), stomatitis (4%), and increased amylase (4%).
Another therapy in developed, poziotinib, has also shown potential for patients withEGFRexon 20 insertions, according to findings presenting at the IASLC 19th World Conference on Lung Cancer.3This therapy induced a confirmed ORR of 43% among evaluable patients withEGFRexon 20 mutant NSCLC.
“Treatment with available EGFR TKIs, like afatinib or osimertinib, have limited potency forEGFRexon 20 insertion variants,” Riely said. “Poziotinib has limited selectivity when you compare theEGFRexon 20 versusEGFRwild-type. TAK-788 potentially inhibitsEGFRexon 20 mutations and there is some selectivity over wild-type EGFR.”
Studies exploring both treatments are ongoing. The EXCLAIM expansion cohort is currently examining TAK-788 at 160 mg daily in 91 patients (NCT02716116). Additionally, a phase II study exploring poziotinib continues to recruit participants (NCT03066206).
BLU-667 was originally explored in a dose escalation study that uncovered a maximum tolerated dose of 400 mg per day. This dose is being explored in an ongoing expansion trial across variousRETfusion-positive malignancies. In this expansion study, 120 patients withRET-positive advanced NSCLC have already received treatment with the 400 mg dose of BLU-667.
The median age of patients in the study was 60 years, and 62% had an ECOG performance status of 1 or 2. Brain metastases were present for 40% of patients at baseline and patients had received a median of 2 prior therapies, including chemotherapy 77% or a checkpoint inhibitor 39%. The most common fusion partner was KIF5B (66%).
A majority of responses were observed at the first scan, and 82% of patients remained on treatment at the data cutoff on April 28, 2019. The median duration of response had not yet been achieved, with many continuing to respond for longer than 24 months. Responses were seen regardless of RET fusion partner, CNS involvement, and prior frontline therapy, said lead investigator Justin F. Gainor, MD.
The most common treatment-related grade ≥3 toxicities were neutropenia (13%), hypertension (10%), anemia (4%), fatigue (3%), leukopenia (3%), and increased CPK (3%), constipation (2%), AST increase (2%), and ALT increase (2%). Seven percent of patients discontinued treatment due to treatment-related toxicity.
“BLU-667 demonstrates broad and durable antitumor activity in patients withRETfusion-positive lung cancer,” said Gainor, from Massachusetts General Hospital. “We observed activity against intracranial metastases, and in general BLU-667 was well tolerated at the 400 mg dose, with mostly grade 1 and 2 adverse events.”
BLU-667 has also demonstrated efficacy for other types ofRETfusion-positive malignancies, according to Gainor. Partial responses have been seen in 2 out 2 patients with RET+ metastatic pancreatic cancer, in a patient with RET+ intrahepatic bile duct caner, and in 5 out 6 patients treated with RET+ papillary thyroid cancer. Similar adverse events were seen across these otherRET-positive malignancies, Gainor said.
Other RET inhibitors are also currently under development as treatments for patients with lung cancer. In addition to BLU-667, the RET inhibitor LOXO-292 is also currently in development.
In conjunction with the ASCO presentation, Gainor noted that BLU-667 had been granted a breakthrough therapy designation from the FDA, a designation that was also received by LOXO-292. This designation makes both agents eligible for an accelerated approval pathway based upon objective response rates, placing importance on phase II findings.
With the expansion of targeted therapies for NSCLC, ever greater emphasis is placed upon the next-generation sequencing. “There are a lot of great initiatives to drive testing to 100% across the United States,” said Lovly. “As a community, we can expand the reach of precision medicine for lung cancer patients through improved uptake of tumor biomarker testing.”